Global Liposarcoma Pipeline Insight Report 2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Liposarcoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Liposarcoma - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Liposarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Liposarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Liposarcoma.

Liposarcoma Emerging Drugs Chapters

This segment of the Liposarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Liposarcoma Emerging Drugs

Selinexor: Karyopharm Therapeutics

Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. Selinexor, ( XPOVIO), has been approved by the United States Food and Drug Administration (FDA) for relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Selinexor is also currently being evaluated in ongoing Phase 2 and 3 clinical studies in patients with a variety of hematologic and solid tumor malignancies. The drug is in Phase III clinical studies for the treatment of Liposarcoma.

• Cabazitaxel - Sanofi

Cabazitaxel is a third generation taxoid and a semisynthetic derivative of 10-deacetylbaccatin III, which is under development with Sanofi. It is a microtubule inhibitor that binds to tubulin. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions. This drug has been approved by FDA for prostate cancer. Cabazitaxel has completed Phase II clinical studies for the treatment of Liposarcoma.

Liposarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Liposarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Liposarcoma

There are approx. 20+ key companies which are developing the therapies for Liposarcoma. The companies which have their Liposarcoma drug candidates in the most advanced stage, i.e. Phase III include, Karyopharm Therapeutics.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Liposarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Liposarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Liposarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Liposarcoma drugs.

Liposarcoma Report Insights

• Liposarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Liposarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Liposarcoma drugs?
• How many Liposarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Liposarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Liposarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Liposarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Karyopharm Therapeutics
• Sanofi
• Incyte Corporation
• Macrogenics
• Adaptimmune
• Merck KGaA
• GlaxoSmithKline
• Novartis Oncology
• Immune Design
• Syndivia
• TerSera Therapeutics

Key Products

• Selinexor
• Cabazitaxel
• Retifanlimab
• ADP A2M4
• Avelumab
• Letetresgene autoleucel
• Ribociclib
• LV 305
• CMB 305
• SDV-1101
• Telotristat etiprate

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gb33iv